Answers are grounded in this paper and cite their sources.
BACKGROUND: Alzheimer's disease (AD) is the most widespread age-related neurodegenerative disease. Recently, a growing body of evidence suggested the phytochemical use to slow down AD onset and progression. OBJECTIVE: To review the phytochemical role potentially involved in AD treatment. METHOD: A systematic review from existing literature on phytochemicals used in the treatment of AD patients was conducted. Selection criteria included: 1) age≥60 years; 2) AD diagnosis in agreement with the criteria of National Institute on Aging-Alzheimer's Association (NIAAA), and 3) suitable measures to asses cognitive, functional and clinical status. RESULTS: Ninety-seven articles were involved in the present study. Several phytochemicals seem to slow down AD onset, delay disease progression and let recovery through targeting multiple pathological causes by anti-cholinergic, antioxidant and anti-inflammatory features. CONCLUSION: Deeper knowledge on phytochemicals and their specific molecular targets is essential to guarantee safe use of these compounds as an option for AD treatment.
No takes yet. Share an insight, caveat, or question.
D’Onofrio et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: